Logo
Injectable Wegovy (Semaglutide)
Virtual visit

Wegovy® Injection (GLP-1)

Get Wegovy (semaglutide) online — FDA-approved weekly injection for chronic weight management. Licensed providers, same-day prescriptions, insurance accepted.

The only weight loss medication proven to prevent life-threatening cardiovascular events in adults with obesity and known heart disease

Once-weekly injection with proven average weight loss of 15% over 68 weeks—no daily timing restrictions or absorption concerns

Prescribed only if appropriate, with ongoing medical support

Visit options

Costs shown are for the visit only. You'll pay for medication at your preferred pharmacy.

Video Visit

$25

Est. or $100 w/o insurance

Chat Visit

$30

w/o insurance

Most insurance accepted

Board-certified

No hidden fees

Available nationwide

What is Injectable Wegovy®?

Injectable Wegovy® is the gold-standard semaglutide formulation for weight management. It is backed by years of clinical research demonstrating not just weight loss, but meaningful health outcomes that extend life.

What makes Injectable Wegovy® distinct from the newly approved oral version is predictability and proven efficacy. The weekly injection delivers consistent, reliable absorption without the strict morning timing requirements or absorption variability of the oral formulation. Inject once a week at any time of day, with or without food—and you're done.

Taken once weekly via subcutaneous injection in the abdomen, thigh, or upper arm, Injectable Wegovy® works by mimicking the GLP-1 hormone to reduce appetite, slow gastric emptying, and improve metabolic health. Most patients start at a lower dose and increase to the maintenance dose of over 16-20 weeks based on tolerance.

Reduces appetite and increases feelings of fullness

By activating GLP-1 receptors in areas of the brain that regulate hunger and satiety—helping you eat less without constantly fighting cravings or feeling deprived

Slows gastric emptying

To keep food in your stomach longer, preventing post-meal blood sugar spikes and creating a sustained sense of fullness that makes it easier to maintain a reduced-calorie diet.

Improves metabolic health

By enhancing insulin sensitivity and helping your body use glucose more effectively—benefits that extend beyond the scale to markers like blood pressure, cholesterol, and inflammation.

Protects your cardiovascular system.

In the SELECT trial, Injectable Wegovy® reduced the risk of major adverse cardiovascular events by 20% in adults with established heart disease and obesity—translating to fewer heart attacks, strokes, and cardiovascular deaths.

Virtual visit with clinician

Ongoing support, always available.

You’ll be treated by experts with years of experience in managing weight, metabolic health, and related conditions such as hypertension and insulin resistance.

Our clinicians will monitor progress. If medication is prescribed, we will adjust dosing and manage side effects safely. If lab testing is ordered, we review results and refine your plan accordingly. You’re never left navigating alone.

Injectable Wegovy (Semaglutide)

How Injectable Wegovy® can change your day-to-day

Freedom from food obsession

Many patients describe a dramatic reduction in "food noise"—fewer intrusive thoughts about eating, less preoccupation with the next meal, and a greater sense of mental clarity that wasn't there before.

Confidence in long-term health protection

Knowing you're not just losing weight but actively reducing your risk of heart attack, stroke, and cardiovascular death changes how you think about your future—especially if you have established heart disease.

A sustainable routine that fits your life

One injection per week, at any time of day, with or without food. No daily pills, no 30-minute wait before eating, no worrying about absorption. You inject on your schedule and move on with your day.

With General Medicine, weight loss is a part of your long-term care plan.

Whether you want access to a GLP-1 or a more comprehensive approach, you’ll always start with an expert clinician. They evaluate your full health history, lifestyle, and past weight-loss attempts to build a plan designed for long-term health.
Your care plan
Clinician
1

Share your health story

Complete a brief medical questionnaire so our clinicians can understand your goals, history, and unique challenges.

2

Meet your clinician

Book a virtual weight-loss visit with a licensed physician who evaluates your needs and determines if medication is right for you. It’s covered by insurance.

3

Get your care plan

If eligible, your clinician will prescribe the most appropriate treatment—GLP-1 or non-GLP-1. They’ll also help you manage related conditions such as hypertension or metabolic syndrome.

4

Start seeing results

Track your progress, schedule follow-up visits anytime, and adjust your treatment as your body evolves.

Clinical outcomes and care14.9%
In the STEP 1 clinical trial, adults with obesity taking Injectable Wegovy® 2.4 mg achieved an average weight loss of 14.9% (approximately 33.7 pounds) over 68 weeks, compared to 2.4% on placebo.

In the SELECT trial, Injectable Wegovy® reduced the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% in adults with established heart disease and obesity over a median of 39.8 months. The trial also showed a 15% reduction in cardiovascular death and a 19% reduction in death from any cause.

More than two-thirds of participants in STEP trials achieved at least 10% body weight reduction, and approximately one-third achieved at least 20% weight reduction with Injectable Wegovy® 2.4 mg.

What our customers have to say

Hear from people who felt heard, understood, and supported on General Medicine's weight loss program

“General Medicine helped me accomplish what I couldn't do alone, and was always there if I had a question.”

Melinda

“With regular checkups and consistent guidance, I was able to improve my blood pressure, maintain healthier blood sugar levels, and build better daily habits around nutrition and exercise. Having ongoing support and preventive care made it easier to stay accountable and make steady progress toward a healthier lifestyle.”

Brandy

“It was so simple to access the care that I needed to improve my health and life.”

Brandon

“I love the easy access and flexible appointments. The communication and how they always check in for you is a big thing.”

Waldo

Start your clinician-led weight-loss journey today.

Frequently asked questions about Injectable Wegovy®

How is Injectable Wegovy® different from Oral Wegovy® or other GLP-1 medications?

Injectable Wegovy® and Oral Wegovy® contain the same active ingredient (semaglutide) and are both FDA-approved for weight management and cardiovascular risk reduction. The key differences are in administration and convenience. Injectable Wegovy® is taken once weekly at any time of day, with or without food, and has the most extensive clinical evidence base including the SELECT cardiovascular outcomes trial.

Oral Wegovy® is a daily pill that requires taking on an empty stomach with no more than 4 oz of water, then waiting 30 minutes before eating, drinking, or taking other medications—which can be challenging for some patients. Injectable Wegovy® also has more predictable absorption and is the only formulation approved for adolescents. Compared to other GLP-1s, Injectable Wegovy® is the only weight loss medication proven to reduce cardiovascular events in patients with established heart disease.

How long does it take to work?

Most patients notice appetite changes within the first few weeks. Meaningful weight loss typically becomes visible by 8-12 weeks, with results continuing to build over time. The STEP trials showed peak weight loss at approximately 68 weeks of treatment.

Can I switch from Injectable to Oral Wegovy® later?

Yes, but it should be done under clinician guidance. Your General Medicine clinician can help you transition between formulations based on your goals, lifestyle, and how well you're tolerating treatment. Keep in mind that switching requires adjusting to a new dosing schedule and routine.

Is Injectable Wegovy® safe long-term?

Injectable Wegovy® has been studied in clinical trials up to 68 weeks with a well-characterized safety profile. The SELECT cardiovascular outcomes trial followed patients for a median of 39.8 months (over 3 years), demonstrating sustained safety and cardiovascular benefits. Long-term use should always be supervised by a clinician who can monitor your health and adjust treatment as needed.

Will insurance cover Injectable Wegovy®?

Insurance coverage varies by plan. Many commercial insurance plans cover Injectable Wegovy® for weight management in adults with obesity with at least one weight-related comorbidity. As of 2024, some plans also cover it for cardiovascular risk reduction in adults with established heart disease. Medicare coverage for weight loss is limited, though some Medicare Advantage plans may cover it for cardiovascular indications. Eligible commercially insured patients may pay as little as $25 per month with Novo Nordisk's savings card (maximum savings $100/month). Our team can help you navigate your insurance coverage.

What's the difference between Injectable Wegovy® and Ozempic®?

Both contain semaglutide, but they have different FDA-approved indications and dosing. Injectable Wegovy® (up to 2.4 mg weekly) is approved for chronic weight management and cardiovascular risk reduction in patients with obesity. Ozempic® (up to 2 mg weekly) is approved for type 2 diabetes, with indications for blood sugar control, cardiovascular risk reduction, and kidney disease protection in patients with diabetes. While both cause weight loss, Ozempic® is not FDA-approved for weight loss in patients without diabetes.

What are the side effects?

The most common side effects of Injectable Wegovy® are typically mild to moderate, occur most often during dose escalation, and tend to improve over time. They may include: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, and fatigue. More serious but less common risks include pancreatitis, gallbladder problems, kidney problems,, changes in vision, low blood sugar, and increased heart rate. Injectable Wegovy® should not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Injection site reactions (redness, swelling, bruising) can occur but are generally mild and resolve quickly. Rotating injection sites each week minimizes this risk.

Has Wegovy® been studied for use in adolescents?

In adolescents aged 12-17 with obesity, Injectable Wegovy® produced a mean reduction in BMI of 16.1% compared to an increase of 0.6% with placebo over 68 weeks.

What has Wegovy® been approved for?

Injectable Wegovy® was approved by the FDA in 2021 for chronic weight management and expanded in 2024 to include cardiovascular risk reduction.

The clinical trials that demonstrated cardiovascular benefits (SELECT trial) and the landmark weight loss data (STEP trials) were all conducted with the injectable formulation, not the pill.

Logo

© 2026 Path Healthcare Systems Corp.